antibody

JAG1 / Jagged 1 Antibody (clone HMJ1-29) LS-C188668

LS-C188668

monoclonal

hamsters

nonconjugated

HMJ1-29

The same clone is also sold as:

• Invitrogen: 12-3391-82, 16-3391-050, 16-3391-85, 16-3391-38, 12-3391-80, 16-3391-025
• BioLegend: 130915, 130908, 130907, 130902, 130914, 130913, 130917
• Bio-Rad: MCA5707GA

human, mouse

flow cytometry, immunohistochemistry - frozen section

LS-C188668

Mouse

Hamster

JAG1 / Jagged 1 Antibody (clone HMJ1-29) LS-C188668

Recognizes CD339, otherwise known as Jagged1, one of the five major ligands of the Notch signalling pathway, which is activated through the binding of specific ligands to the Notch receptors Notch 1-4. The Notch signalling pathway is an evolutionarily conserved pathway in multi-cellular organisms, which is vital for cell-cell communication, important during fundamental developmental and physiological processes, including regulation of cell fate decisions during neuronal, cardiac and endocrine development, stem cell haematopoiesis, thymic T-cell development, and both tumor progression and suppression. Ligation of Notch receptors by their specific ligands, Jagged1 (CD339), Jagged2, Delta like-1 (DLL1), DLL3 and DLL4, on physically adjacent signal receiving cells, induces proteolysis of the receptors by ADAM-family metalloproteases and gamma-secretase complex, within the transmembrane domain, releasing the Notch intracellular domain (NICD) to translocate to the nucleus. Subsequent signal transduction then occurs through either the CSL-NICD-Mastermind complex cascade (canonical pathway), or NF-kappaB-NICD and CSL-NICD-Deltex complex signalling cascades (non-canonical pathway). The canonical pathway inhibits the differentiation of stem cells or progenitor cells, whilst the non-canonical pathway promotes differentiation. Jagged1 signalling is implicated in cell-fate decisions during haematopoiesis, as well as in both early and late stages of mammalian cardiovascular development, and is involved in the inhibition of myoblast differentiation. Studies have shown a significant increase in the expression of Jagged1 in metastatic prostate cancer, compared with localized prostate cancer or benign prostatic tissues, implicating Jagged1 as a biomarker to facilitate their differentiation. In humans, mutations in the JAG1 gene are responsible for the autosomal dominant multi-system developmental disorder known as Alagille syndrome type 1 (ALGS1), and also for the congenital heart anomaly tetralogy of Fallot (TOF). Clone HMJ1-29 has been shown to cross-react with rat mast cell line RBL-2H3 and Y3 myeloma cells, in flow cytometry.

Monoclonal

HMJ1-29

Unconjugated

PBS, 0.09% Sodium Azide

Cells

Jagged1-expressing CHO cells.

Protein G purified

Store at 4°C or at -20°C. Store undiluted. Avoid freeze-thaw cycles. Microcentrifugation recommended if solution contains precipitate.

IgG

JAG1 / Jagged 1

JAG1

Mouse

Flo, IHC-Fr

Jagged 1 antibody LS-C188668 is an unconjugated hamster monoclonal antibody to mouse Jagged 1 (JAG1). Validated for Flow and IHC.

JAG1, AGS, AHD, Alagille syndrome, CD339 antigen, HJ1, Jagged1, JAGL1, Jagged, Jagged 1, Protein jagged-1, AWS, CD339, Soluble protein jagged

Worldwide